See more : Arogo Capital Acquisition Corp. (AOGOU) Income Statement Analysis – Financial Results
Complete financial analysis of Guardion Health Sciences, Inc. (GHSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardion Health Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- West Shore Bank Corp. (WSSH) Income Statement Analysis – Financial Results
- Winpak Ltd. (WIPKF) Income Statement Analysis – Financial Results
- Hisaka Works, Ltd. (6247.T) Income Statement Analysis – Financial Results
- Coca-Cola FEMSA, S.A.B. de C.V. (COCSF) Income Statement Analysis – Financial Results
- Spindox S.p.A. (SPN.MI) Income Statement Analysis – Financial Results
Guardion Health Sciences, Inc. (GHSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.guardionhealth.com
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.25M | 11.05M | 7.23M | 1.89M | 902.94K | 942.15K | 437.35K | 141.03K | 112.81K | 164.58K | 260.36K |
| Cost of Revenue | 6.85M | 6.53M | 4.12M | 1.95M | 341.32K | 398.18K | 175.47K | 75.70K | 50.07K | 145.53K | 168.88K |
| Gross Profit | 5.39M | 4.52M | 3.11M | -56.79K | 561.62K | 543.97K | 261.88K | 65.33K | 62.74K | 19.05K | 91.48K |
| Gross Profit Ratio | 44.04% | 40.91% | 43.00% | -3.01% | 62.20% | 57.74% | 59.88% | 46.32% | 55.61% | 11.58% | 35.14% |
| Research & Development | 150.68K | 193.80K | 64.36K | 160.98K | 194.31K | 231.85K | 259.46K | 64.03K | 401.91K | 43.44K | 259.79K |
| General & Administrative | 7.48M | 9.58M | 11.20M | 6.83M | 7.43M | 4.93M | 4.68M | 3.31M | 5.61M | 638.00K | 616.70K |
| Selling & Marketing | 1.70M | 2.07M | 2.32M | 1.45M | 1.87M | 1.52M | 599.93K | 389.11K | 180.13K | 46.77K | 51.60K |
| SG&A | 9.19M | 11.65M | 13.53M | 8.28M | 9.30M | 6.46M | 5.28M | 3.70M | 5.79M | 684.77K | 668.30K |
| Other Expenses | 394.55K | 3.57M | 10.14M | 0.00 | 1.22M | 0.00 | 0.00 | 174.04K | -1.70M | 0.00 | 0.00 |
| Operating Expenses | 9.73M | 11.84M | 13.59M | 8.45M | 9.50M | 6.69M | 5.54M | 3.76M | 6.19M | 728.21K | 928.09K |
| Cost & Expenses | 16.58M | 18.37M | 17.72M | 10.39M | 9.84M | 7.09M | 5.72M | 3.84M | 6.24M | 873.74K | 1.10M |
| Interest Income | 379.52K | 152.57K | 1.80K | 7.27K | 258.37K | 0.00 | 0.00 | 0.00 | 0.00 | 611.34K | 406.07K |
| Interest Expense | 0.00 | 15.35M | 0.00 | 7.27K | 258.37K | 2.29K | 23.73K | 1.10M | 752.95K | 0.00 | 0.00 |
| Depreciation & Amortization | 19.42K | 1.25M | 910.37K | 219.60K | 625.79K | 295.67K | 118.82K | 60.13K | 53.74K | 43.23K | 8.84K |
| EBITDA | -3.92M | -6.07M | -9.70M | -8.34M | -9.99M | -7.47M | -5.16M | -4.58M | -8.03M | -665.92K | -827.77K |
| EBITDA Ratio | -32.02% | 15.22% | -132.36% | -438.27% | -966.13% | -620.71% | -1,180.44% | -2,578.07% | -6,892.95% | -404.61% | -317.94% |
| Operating Income | -4.34M | 432.68K | -10.48M | -8.55M | -8.93M | -6.14M | -5.28M | -3.95M | -6.39M | -709.15K | -836.61K |
| Operating Income Ratio | -35.40% | 3.92% | -144.94% | -452.51% | -989.37% | -652.09% | -1,207.60% | -2,797.79% | -5,663.22% | -430.88% | -321.33% |
| Total Other Income/Expenses | 4.49M | 2.50M | 1.80K | -19.93K | -381.37K | -1.62M | -23.73K | -1.80M | -2.45M | -611.34K | -406.07K |
| Income Before Tax | 158.03K | -14.92M | -24.75M | -8.57M | -10.88M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Income Before Tax Ratio | 1.29% | -135.05% | -342.11% | -453.56% | -1,204.77% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| Income Tax Expense | 0.00 | 15.35M | 672.79K | 7.27K | 258.37K | -1.62M | 0.00 | 1.10M | -946.66K | 0.00 | 0.00 |
| Net Income | 158.03K | -30.28M | -24.75M | -8.58M | -11.14M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Net Income Ratio | 1.29% | -274.01% | -342.11% | -453.95% | -1,233.38% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| EPS | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.39 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| EPS Diluted | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.09 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| Weighted Avg Shares Out | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.70K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
| Weighted Avg Shares Out (Dil) | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.91K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
Guardion Health Sciences Announces Filing of Certificate of Dissolution
Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
Guardion Health Sciences Announces
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Why Is Guardion Health (GHSI) Stock Up 66% Today?
What made Guardion Health stock double on Wednesday?
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor's Best Inc.
Source: https://incomestatements.info
Category: Stock Reports